#Immunotherapy
#ImmuneRelatedAdverseEvents
#Biomarkers
#ICOS+ CD4 #Tcells define #Susceptibility to anti-PD1-induced #Lung #Pathology in the #Aged
#Bcells #Antibodies #TertiaryLymphoidStructures
Breaking Open Access Study @jci-insight.bsky.social
insight.jci.org/articles/vie...
#Immunotherapy
#ImmuneRelatedAdverseEvents
#Biomarkers
#ICOS+ CD4 #Tcells define #Susceptibility to anti-PD1-induced #Lung #Pathology in the #Aged
#Bcells #Antibodies #TertiaryLymphoidStructures
Breaking Open Access Study @jci-insight.bsky.social
insight.jci.org/articles/vie...
www.cell.com/immunity/ful...
www.cell.com/immunity/ful...
doi.org/10.59717/j.x...
#TumorMicroenvironment
doi.org/10.59717/j.x...
#TumorMicroenvironment
One kind of immune messenger cell builds then keeps tumor immune hubs alive. Would you want treatments that boost these cells in tumors?
Paper: doi.org/10.1158/2159-8290.cd-rw2026-075
#dendriticcells #tertiarylymphoidstructures #cancerimmunotherapy #paperoftheday
One kind of immune messenger cell builds then keeps tumor immune hubs alive. Would you want treatments that boost these cells in tumors?
Paper: doi.org/10.1158/2159-8290.cd-rw2026-075
#dendriticcells #tertiarylymphoidstructures #cancerimmunotherapy #paperoftheday
Major #CD40 #TherapeuticAntibody Success now breaking
@cp-cancercell.bsky.social
First-in-Human study of Fc-optimised CD40 agonistic Antibody elicits #TertiaryLymphoidStructures & systemic anti-Tumor #Immunity in Metastatic #Cancer
Fantastic work 👏
Major #CD40 #TherapeuticAntibody Success now breaking
@cp-cancercell.bsky.social
First-in-Human study of Fc-optimised CD40 agonistic Antibody elicits #TertiaryLymphoidStructures & systemic anti-Tumor #Immunity in Metastatic #Cancer
Fantastic work 👏
#ImmuneResponse #Immunotherapy
#ImmuneResponse #Immunotherapy
#IL33 #ILC2 #TertiaryLymphoidStructures #PancreaticCancer #CancerImmunology
www.nature.com/articles/s41...
#IL33 #ILC2 #TertiaryLymphoidStructures #PancreaticCancer #CancerImmunology
www.nature.com/articles/s41...